Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567970 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
A Phase 1 study of Metastatic Cancer, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00567970 is a Phase 1 study of Metastatic Cancer that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00567970, a Phase 1 study of Metastatic Cancer, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiation therapy in treating patients with liver metastases.
Conditions Studied
Interventions
- RADIATION stereotactic body radiation therapy
- PROCEDURE quality-of-life assessment
Study Locations (1)
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-04-02 |
| Est. Completion | 2016-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567970
The ClinicalTrials.gov registry entry for NCT00567970 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which stereotactic body radiation therapy is the first listed.
NCT00567970 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00567970 about?
NCT00567970 is a clinical study titled "Stereotactic Radiation Therapy in Treating Patients With Liver Metastases". RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiation therapy in treating patients with liver metastases.
What is the current status of trial NCT00567970?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-04-02. Estimated completion is 2016-04-21.
What conditions does trial NCT00567970 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT00567970?
The interventions under investigation include: stereotactic body radiation therapy (RADIATION), quality-of-life assessment (PROCEDURE).
Who is sponsoring clinical trial NCT00567970?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00567970 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.